CHMP recommends EU approval of SC formulation of Lunsumio for people with R/R follicular lymphoma September 23, 2025
Ph 3 PiNACLE – H2H of rondecabtagene autoleucel (ronde-cel, aka LYL314) vs liso-cel or axi-cel initiated in R/R LBCL September 9, 2025
CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value September 9, 2025
Ph 1 trials for TLN-121, TLN-254 in lymphoma and TLN-372 in patients with cancers expressing certain KRAS mutations initiated September 9, 2025
Epcoritamab Demonstrates High Response Rates, Safe Outpatient Use in Ph 2 EPCORE® NHL-6 Study in DLBCL September 9, 2025
Positive Topline Results for Sonrotoclax in R/R MCL Announced; primary endpoint of ORR met September 3, 2025
Ongoing Ph 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma showed 66% ORR and 50% CR in NHL patients September 3, 2025
First patient dosed in registrational clinical trial of mesutoclax for the treatment of BTKi-experienced mantle cell lymphoma in China August 26, 2025
European Commission Approves Tablet Formulation of BRUKINSA® for All Approved Indications August 26, 2025
CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
FDA Grants Priority Review to Breyanzi (lisocabtagene maraleucel) for R/R Marginal Zone Lymphoma August 11, 2025
Patient death triggers switch to standard FC Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation for LBCL August 5, 2025
Complete Response Reported in Heavily Pre-Treated Lymphoma Patient with LP-284 in Ph 1 Trial July 29, 2025
FDA issues CRL for Supplemental BLA for Columvi® (glofitamab-gxbm) + GemOx combo for R/R DLBCL patients not candidates for autoSCT July 23, 2025
Encouraging Response Rates Announced from Ph 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL July 15, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of 1L MCL patients eligible for autologous stem cell transplant July 1, 2025
FDA grants Fast Track Designation for SGR-1505 for the Treatment of R/R Waldenström Macroglobulinemia July 1, 2025
Marker Therapeutics and Cellipont Bioservices to Advance cGMP Manufacturing of MT-601 for Patients with Lymphoma June 24, 2025
